FGF21 may represent a promising next-generation preventive and therapeutic strategy that warrants comprehensive testing in human clinical trials of obesity-associated pancreatic cancer, pancreatitis, and other inflammation-related disease states such as NASH and hepatocellular cancer. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.